CA2270056A1 - Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes - Google Patents
Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes Download PDFInfo
- Publication number
- CA2270056A1 CA2270056A1 CA002270056A CA2270056A CA2270056A1 CA 2270056 A1 CA2270056 A1 CA 2270056A1 CA 002270056 A CA002270056 A CA 002270056A CA 2270056 A CA2270056 A CA 2270056A CA 2270056 A1 CA2270056 A1 CA 2270056A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- cis
- formula
- compound
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000262 estrogen Substances 0.000 title claims abstract description 64
- 229940011871 estrogen Drugs 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 230000002265 prevention Effects 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 18
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 19
- -1 heterocyclic amine Chemical class 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- 206010065687 Bone loss Diseases 0.000 claims description 11
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 238000010511 deprotection reaction Methods 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 208000001132 Osteoporosis Diseases 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010000242 Abortion threatened Diseases 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 7
- 208000008899 Habitual abortion Diseases 0.000 claims description 7
- 206010020112 Hirsutism Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 208000005985 Threatened Abortion Diseases 0.000 claims description 7
- 206010071018 Urogenital atrophy Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 230000006408 female gonad development Effects 0.000 claims description 7
- 230000006651 lactation Effects 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims description 6
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 6
- 206010027514 Metrorrhagia Diseases 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 206010021639 Incontinence Diseases 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 230000002152 alkylating effect Effects 0.000 claims description 5
- 238000006880 cross-coupling reaction Methods 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000011010 flushing procedure Methods 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 230000029964 regulation of glucose metabolic process Effects 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- MCAAKTPWZDIZGG-LRHLLKFHSA-N (3r,4s)-3-phenyl-4-[4-(10-pyrrolidin-1-yldecoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCCCCCN1CCCC1 MCAAKTPWZDIZGG-LRHLLKFHSA-N 0.000 claims description 4
- KVSBXTUINHYFTA-LRHLLKFHSA-N (3r,4s)-3-phenyl-4-[4-(10-pyrrolidin-1-yldecoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 KVSBXTUINHYFTA-LRHLLKFHSA-N 0.000 claims description 4
- PCBYGJYGFMUQFI-JSXFGMRASA-N (3r,4s)-3-phenyl-4-[4-(12-pyrrolidin-1-yldodecoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCCCCCCCN1CCCC1 PCBYGJYGFMUQFI-JSXFGMRASA-N 0.000 claims description 4
- MSZCMMBXIGHNFQ-JSXFGMRASA-N (3r,4s)-3-phenyl-4-[4-(12-pyrrolidin-1-yldodecoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 MSZCMMBXIGHNFQ-JSXFGMRASA-N 0.000 claims description 4
- RFKYLSUUYGYRRM-SMCANUKXSA-N (3r,4s)-3-phenyl-4-[4-(6-pyrrolidin-1-ylhexoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCN1CCCC1 RFKYLSUUYGYRRM-SMCANUKXSA-N 0.000 claims description 4
- WBEKZTZIAUGMJG-SMCANUKXSA-N (3r,4s)-3-phenyl-4-[4-(6-pyrrolidin-1-ylhexoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 WBEKZTZIAUGMJG-SMCANUKXSA-N 0.000 claims description 4
- XSUBMTWBMHIMSR-CDZUIXILSA-N (3r,4s)-3-phenyl-4-[4-(7-pyrrolidin-1-ylheptoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 XSUBMTWBMHIMSR-CDZUIXILSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 239000012039 electrophile Substances 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 claims description 4
- YGZVWLYLCBOBGJ-GIWKVKTRSA-N (3r,4s)-3-phenyl-4-[4-(11-pyrrolidin-1-ylundecoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCCCCCCN1CCCC1 YGZVWLYLCBOBGJ-GIWKVKTRSA-N 0.000 claims description 3
- XRYHBRYPVSOINX-GIWKVKTRSA-N (3r,4s)-3-phenyl-4-[4-(11-pyrrolidin-1-ylundecoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 XRYHBRYPVSOINX-GIWKVKTRSA-N 0.000 claims description 3
- NDDKTRSBZBKDLS-JDXGNMNLSA-N (3r,4s)-3-phenyl-4-[4-(5-pyrrolidin-1-ylpentoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCN1CCCC1 NDDKTRSBZBKDLS-JDXGNMNLSA-N 0.000 claims description 3
- YNPQNTHVZOELEV-JDXGNMNLSA-N (3r,4s)-3-phenyl-4-[4-(5-pyrrolidin-1-ylpentoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCN3CCCC3)=CC=2)=CC=CC=C1 YNPQNTHVZOELEV-JDXGNMNLSA-N 0.000 claims description 3
- HLDWKFAVIHSIQE-CDZUIXILSA-N (3r,4s)-3-phenyl-4-[4-(7-pyrrolidin-1-ylheptoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCCN1CCCC1 HLDWKFAVIHSIQE-CDZUIXILSA-N 0.000 claims description 3
- WNXOCOSJUXYVPJ-WEZIJMHWSA-N (3r,4s)-3-phenyl-4-[4-(8-pyrrolidin-1-yloctoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCCCN1CCCC1 WNXOCOSJUXYVPJ-WEZIJMHWSA-N 0.000 claims description 3
- USRISCCNOFMKPS-WEZIJMHWSA-N (3r,4s)-3-phenyl-4-[4-(8-pyrrolidin-1-yloctoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 USRISCCNOFMKPS-WEZIJMHWSA-N 0.000 claims description 3
- IMGGRDZSXPRXDW-UHFFFAOYSA-N 4-[4-(4-morpholin-4-ylbutoxy)phenyl]-3-phenyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1OC2=CC(O)=CC=C2C(C=2C=CC(OCCCCN3CCOCC3)=CC=2)C1C1=CC=CC=C1 IMGGRDZSXPRXDW-UHFFFAOYSA-N 0.000 claims description 3
- UJFZTNOSQFRBOR-UHFFFAOYSA-N 4-[4-(6-morpholin-4-ylhexoxy)phenyl]-3-phenyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1OC2=CC(O)=CC=C2C(C=2C=CC(OCCCCCCN3CCOCC3)=CC=2)C1C1=CC=CC=C1 UJFZTNOSQFRBOR-UHFFFAOYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 101100533888 Hypocrea jecorina (strain QM6a) sor4 gene Proteins 0.000 claims description 3
- 101100533877 Hypocrea jecorina (strain QM6a) sor8 gene Proteins 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000007819 coupling partner Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- POOKMKUEQPGERL-TWJUONSBSA-N (3r,4s)-3-phenyl-4-[4-(9-pyrrolidin-1-ylnonoxy)phenyl]-3,4-dihydro-2h-chromen-7-ol Chemical compound C1([C@H]2[C@H](C3=CC=C(C=C3OC2)O)C=2C=CC(OCCCCCCCCCN3CCCC3)=CC=2)=CC=CC=C1 POOKMKUEQPGERL-TWJUONSBSA-N 0.000 claims description 2
- GTQHJCOHNAFHRE-UHFFFAOYSA-N 1,10-dibromodecane Chemical compound BrCCCCCCCCCCBr GTQHJCOHNAFHRE-UHFFFAOYSA-N 0.000 claims description 2
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 claims description 2
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 claims description 2
- DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 claims description 2
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 230000002254 contraceptive effect Effects 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000011814 protection agent Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- NKVBJEUUHWYLMI-TWJUONSBSA-N (3r,4s)-3-phenyl-4-[4-(9-pyrrolidin-1-ylnonoxy)phenyl]-3,4-dihydro-2h-chromen-6-ol Chemical compound C1=CC([C@@H]2[C@@H](COC3=CC=C(C=C32)O)C=2C=CC=CC=2)=CC=C1OCCCCCCCCCN1CCCC1 NKVBJEUUHWYLMI-TWJUONSBSA-N 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 235000013350 formula milk Nutrition 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 238000009164 estrogen replacement therapy Methods 0.000 description 7
- 230000009245 menopause Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000037182 bone density Effects 0.000 description 6
- 210000000172 cytosol Anatomy 0.000 description 6
- 102000015694 estrogen receptors Human genes 0.000 description 6
- 108010038795 estrogen receptors Proteins 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000583 progesterone congener Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229940046836 anti-estrogen Drugs 0.000 description 4
- 230000001833 anti-estrogenic effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000328 estrogen antagonist Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000013223 sprague-dawley female rat Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- FTTLVAAILKBGEZ-UHFFFAOYSA-N 4-[10-[4-(7-benzyl-3-phenyl-3,4-dihydro-2h-chromen-4-yl)phenoxy]decyl]morpholine Chemical compound C=1C=C(C2C3=CC=C(CC=4C=CC=CC=4)C=C3OCC2C=2C=CC=CC=2)C=CC=1OCCCCCCCCCCN1CCOCC1 FTTLVAAILKBGEZ-UHFFFAOYSA-N 0.000 description 2
- SPHRHRDPZQOPCF-UHFFFAOYSA-N 4-[4-(10-morpholin-4-yldecoxy)phenyl]-3-phenyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1OC2=CC(O)=CC=C2C(C=2C=CC(OCCCCCCCCCCN3CCOCC3)=CC=2)C1C1=CC=CC=C1 SPHRHRDPZQOPCF-UHFFFAOYSA-N 0.000 description 2
- GGSGGSVRNVINTC-UHFFFAOYSA-N 4-[4-[6-(dibutylamino)hexoxy]phenyl]-3-phenyl-3,4-dihydro-2h-chromen-7-ol Chemical compound C1=CC(OCCCCCCN(CCCC)CCCC)=CC=C1C1C2=CC=C(O)C=C2OCC1C1=CC=CC=C1 GGSGGSVRNVINTC-UHFFFAOYSA-N 0.000 description 2
- ZLBNSTMUEYCADR-UHFFFAOYSA-N 4-[6-[4-(3-phenyl-7-phenylmethoxy-3,4-dihydro-2h-chromen-4-yl)phenoxy]hexyl]morpholine Chemical compound C=1C=C(C2C3=CC=C(OCC=4C=CC=CC=4)C=C3OCC2C=2C=CC=CC=2)C=CC=1OCCCCCCN1CCOCC1 ZLBNSTMUEYCADR-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010020100 Hip fracture Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- ILZWEPMCHDPDBA-UHFFFAOYSA-N 2,3-diphenyl-3,4-dihydro-2h-chromene Chemical compound O1C2=CC=CC=C2CC(C=2C=CC=CC=2)C1C1=CC=CC=C1 ILZWEPMCHDPDBA-UHFFFAOYSA-N 0.000 description 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical group C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LUEGGYSDOMHJCB-UHFFFAOYSA-N 4-[4-(6-bromohexoxy)phenyl]-3-phenyl-7-phenylmethoxy-3,4-dihydro-2h-chromene Chemical compound C1=CC(OCCCCCCBr)=CC=C1C1C2=CC=C(OCC=3C=CC=CC=3)C=C2OCC1C1=CC=CC=C1 LUEGGYSDOMHJCB-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LISATCDUEIDLRM-UHFFFAOYSA-N n,n-dibutyl-6-[4-(3-phenyl-7-phenylmethoxy-3,4-dihydro-2h-chromen-4-yl)phenoxy]hexan-1-amine Chemical compound C1=CC(OCCCCCCN(CCCC)CCCC)=CC=C1C1C2=CC=C(OCC=3C=CC=CC=3)C=C2OCC1C1=CC=CC=C1 LISATCDUEIDLRM-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 101150025395 trkA gene Proteins 0.000 description 1
- 101150113435 trkA1 gene Proteins 0.000 description 1
- 230000007497 verbal memory Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK119996 | 1996-10-28 | ||
DK1199/96 | 1996-10-28 | ||
PCT/DK1997/000485 WO1998018778A1 (en) | 1996-10-28 | 1997-10-28 | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2270056A1 true CA2270056A1 (en) | 1998-05-07 |
Family
ID=8102089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002270056A Abandoned CA2270056A1 (en) | 1996-10-28 | 1997-10-28 | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0934299A1 (xx) |
JP (1) | JP2001502710A (xx) |
AU (1) | AU4772297A (xx) |
CA (1) | CA2270056A1 (xx) |
IL (1) | IL129618A0 (xx) |
NO (1) | NO992005L (xx) |
WO (1) | WO1998018778A1 (xx) |
ZA (1) | ZA979649B (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU722089B2 (en) * | 1996-12-13 | 2000-07-20 | Chugai Seiyaku Kabushiki Kaisha | Novel benzopyran derivatives |
JP2000119187A (ja) * | 1998-10-15 | 2000-04-25 | Taisho Pharmaceut Co Ltd | 抑うつ気分の予防または改善用組成物 |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
CN101056868B (zh) | 2004-09-21 | 2012-05-02 | 马休爱德华兹股份有限公司 | 取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用 |
JP6013349B2 (ja) | 2010-11-01 | 2016-10-25 | メイ ファーマ, インク.Mei Pharma, Inc. | 癌の処置のためのイソフラボノイド化合物および方法 |
HUE054998T2 (hu) | 2015-02-02 | 2021-10-28 | Mei Pharma Inc | Kombinációs terápiák emlõrák kezelésében való alkalmazásra |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3340276A (en) * | 1964-04-01 | 1967-09-05 | Ciba Geigy Corp | 3, 4-diphenyl-chromans |
DE1543749A1 (de) * | 1966-02-16 | 1969-12-11 | Merck Ag E | Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen |
US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
HUP9702244A3 (en) * | 1995-01-13 | 1999-12-28 | Novo Nordisk As | Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders |
-
1997
- 1997-10-28 IL IL12961897A patent/IL129618A0/xx unknown
- 1997-10-28 AU AU47722/97A patent/AU4772297A/en not_active Abandoned
- 1997-10-28 WO PCT/DK1997/000485 patent/WO1998018778A1/en not_active Application Discontinuation
- 1997-10-28 EP EP97910266A patent/EP0934299A1/en not_active Withdrawn
- 1997-10-28 JP JP10519944A patent/JP2001502710A/ja active Pending
- 1997-10-28 CA CA002270056A patent/CA2270056A1/en not_active Abandoned
- 1997-10-28 ZA ZA9709649A patent/ZA979649B/xx unknown
-
1999
- 1999-04-27 NO NO992005A patent/NO992005L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0934299A1 (en) | 1999-08-11 |
WO1998018778A1 (en) | 1998-05-07 |
NO992005L (no) | 1999-06-25 |
IL129618A0 (en) | 2000-02-29 |
NO992005D0 (no) | 1999-04-27 |
JP2001502710A (ja) | 2001-02-27 |
AU4772297A (en) | 1998-05-22 |
ZA979649B (en) | 1998-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6316494B1 (en) | cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
EP0937060B1 (en) | Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
US5985306A (en) | (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes | |
US5994390A (en) | Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
AU744403B2 (en) | Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
EP0937057B1 (en) | Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
US5919817A (en) | Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
EP0937062B1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
CA2270056A1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
AU4700097A (en) | Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
US5958967A (en) | Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
CA2269970A1 (en) | Novel (+)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
CA2270057A1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
CA2270055A1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
AU9733801A (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
AU9734001A (en) | Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
AU9733601A (en) | Novel (+)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
AU9734501A (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or sydndromes | |
AU9733701A (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related disease or sydnromes | |
AU9733501A (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |